课题基金 / 基金详情

Cellular Heterogeneity and Aging in MDS and AML

Cellular Heterogeneity and Aging in MDS and AML
MDS 和 AML 中的细胞异质性和衰老
批准号:
10664830
负责人:
Austin E Gillen
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-06-30

项目摘要

项目成果

Austin E Gillen的其他基金

相似基金

相关文献

中文摘要
翻译
这一应用的目标是提高现有治疗骨髓增生异常综合征(MDS)的疗效。 和急性髓系白血病(AML)通过识别和表征RNA处理表型预测 与年龄相关的疾病进展和耐药性。目前对这两种毁灭性疾病的治疗方法 仅在少数患者中有效,预测反应仍然具有挑战性。改进 应答率代表着退伍军人的大量未得到满足的需求。像许多其他癌症一样,MDS和AML是 在老龄化人口中最为普遍。适应性肿瘤发生模型认为,这种关联是 随着我们年龄的增长,作用在不同细胞群体上的选择压力发生了变化。MDS和AML也是 以广泛的异质性为特点的。这种异质性在细胞的分子图谱中很明显 患者个体以及不同患者对治疗的反应各不相同。初步数据显示, 在这些疾病中,信使核糖核酸的加工和调控也是高度可变的。因为对这些过程的更改可以 在癌症中起着关键作用,这项建议试图理解在mRNA加工和调控中的可变性 推动MDS和AML的疾病进展和对药物治疗的耐药性。拟议的研究使用了新的 测序方法捕捉MDS和MDS中mRNA加工和调控的全范围异质性 单细胞分辨率的AML。使用原代人和MDS和AML标本,以及小鼠模型 这些研究将使我们能够识别特定的mRNA加工和调控表型,从而使 恶性细胞利用与衰老和药物治疗相关的组织环境的变化。 针对这些表型背后的分子机制将改进治疗并增强 对患有MDS和AML的退伍军人临床结局的预测。除了使用原始标本进行研究外 和动物模型,这一应用程序将利用“大数据”资源来识别临床相关的mRNA 由此产生的签名的处理和规范可以为患者的临床管理提供信息。这一奖项将 支持继续开发软件工具,以解释单细胞RNA加工过程中的变化 测序数据。综上所述,拟议的研究将为相互作用提供重要的新见解 MDS/AML中的mRNA异质性、耐药性和衰老之间的关系,并将识别新的 可用于改善患有这些疾病的退伍军人的治疗目标。
英文摘要
The goal of this application is to increase the efficacy of existing treatments for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) by identifying and characterizing RNA processing phenotypes that predict age-related disease progression and drug resistance. Current therapies for both of these devastating diseases are effective in only a small number of patients and predicting responses remains challenging. Improving response rates represents a substantial unmet need for Veterans. Like many other cancers, MDS and AML are most prevalent in aging populations. The Adaptive Oncogenesis model holds that this association is the result of changing selective pressures acting on heterogeneous populations of cells as we age. MDS and AML are also characterized by extensive heterogeneity. This heterogeneity is evident in the molecular profiling of cells from individual patients, as well as in variable response to treatments across patients. Preliminary data show that mRNA processing and regulation are also highly variable in these diseases. As changes to these processes can play a critical role in cancer, this proposal seeks to understand how variability in mRNA processing and regulation drives disease progression and resistance to drug treatment in MDS and AML. The proposed studies use new sequencing methods to capture the full range of mRNA processing and regulation heterogeneity in MDS and AML at single-cell resolution. Using primary human and MDS and AML specimens, as well as murine models of AML, these studies will allow us to identify specific mRNA processing and regulation phenotypes that allow malignant cells to take advantage of changes to tissue environments associated with aging and drug treatment. Targeting the molecular mechanisms underlying these phenotypes will improve treatments and enhance the prediction of clinical outcomes for Veterans with MDS and AML. In addition to studies using primary specimens and animal models, this application will leverage “big data” resources to identify clinically relevant mRNA processing and regulation signatures from that can inform the clinical management of patients. This award will support the continued development of software tools to interpret changes in RNA processing from single-cell sequencing data. Taken together, the proposed studies will provide important new insights into the interplay between mRNA isoform heterogeneity, drug resistance, and aging in MDS/AML and will identify novel therapeutic targets that can be used to improve the treatment of Veterans with these diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cellular Heterogeneity and Aging in MDS and AML
Cellular Heterogeneity and Aging in MDS and AML
海外基金